The GLP‐1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes
Authors' conclusion
Exenatide therapy reduces serum TSH levels and improves central sensitivity to TH action over 12 months via its effect on weight loss. The effectiveness of weight loss strategies, rather than TH replacement, should be investigated in individuals with obesity and mildly raised serum TSH levels.
Study context
- Population
- Patients with T2D and obesity commenced on exenatide; mean age 53.5 years, 43.8% female, mean BMI 39.8 kg/m²
- Participants
- 112 patients
- Outcome
- Relationship between changes in body weight and serum TSH and resistance to TH indices
- Follow-up
- 12 months
Methodological detailssingle-arm
- Single-arm
Main finding
As reported in the abstract
| Group | Value | Percent body weight loss, mean (95% CI) |
|---|---|---|
| Exenatide | mean −0.25 (95% CI −0.43–-0.06) mU/L | 6.5% (5.0%-8.1%) |
Exenatide
Valuemean −0.25 (95% CI −0.43–-0.06) mU/L
Percent body weight loss, mean (95% CI)6.5% (5.0%-8.1%)
mU/L
- Significant negative nonlinear relationship between change in TSH and % weight loss: TSH change with 5% loss
- −0.25
- TSH change with 10% weight loss
- −0.4
- TSH change with 15% weight loss
- −0.5
- TSH rise with 5% weight gain
- 0.5
Observational data: associations, not effects.
Further findings
- No changes in serum FT4 with weight loss
- Significant reduction in resistance to thyroid hormones (TH) indices
Original publication
The GLP‐1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes. Clin Endocrinol (Oxf). Published 7 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →